Non ‐ invasive prognostic protein biomarker signatures associated with colorectal cancer by Silvia Surinova, Lenka Radová, Meena Choi, Josef Srovnal, Hermann.

Slides:



Advertisements
Similar presentations
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an independent.
Advertisements

Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.
Diagnostic testing II. Previously…. Guidelines for evaluating tests have been discussed – Population spectrum – Reference standard Verification bias –
Introduction Integrative Analysis of Genomic Variants in Carcinogenesis Syed Haider, Arek Kasprzyk, Pietro Lio Artificial Intelligence and Computational.
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.
EMT ☤ MET CRC MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer K. Raghav, W. Wang, G.C. Manyam,
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.
LUNG ADENOCARCINOMAS. CLINICOPATHOLOGICAL STUDY WITH RESPECT TO THE UPCOMING NEW CLASSIFICATION AND EGFR-KRAS MUTATION ANALYSIS IMPLICATIONS. First author:
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
Prognostic value of ER, PR, and HER2 breast cancer biomarkers and AJCC’s TNM staging system on overall survival of Caucasian females with breast cancer.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
Role of CXCR4 and VEGF expression and metastatic locoregional lymphnodes in rectal carcinoma Tatangelo F.*, Avallone A.**, Delrio P.°, Scala S.§, Botti.
Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
Jin MENG Shen FU (DPD 08) Biology 2 - Head/Neck and CNS Tumors
LLG03999 TN Categorization for Rectal and Colon Cancers Based on National Survival Outcome Data 1 Mayo Clinic Cancer Center – Arizona; Scottsdale, AZ 2.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
(1) Genotype-Tissue Expression (GTEx) Largest systematic study of genetic regulation in multiple tissues to date 53 tissues, 500+ donors, 9K samples, 180M.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer by Yun ‐ Yong Park, Kyounghyun Kim,
TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype by Evelyn Fessler, Jarno Drost, Sander R van Hooff, Janneke F Linnekamp,
Bringing next ‐ generation diagnostics to the clinic through synthetic biology by Alexis Courbet, Eric Renard, and Franck Molina EMBO Mol Med. Volume ():e
miRNA-targets cross-talks: key players in glioblastoma multiforme
Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer.
Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,
Immunoscore Prognostic in Colon Cancer
Presented By Michael Lee at 2016 ASCO Annual Meeting
Presented By Deborah Schrag at 2016 ASCO Annual Meeting
Yu-fang huang, yi-hui wu, cheng-yang chou*
MR images analysis of glioma
LL Gunderson1, JM Jessup 2, DJ Sargent 3, FL Greene 4, A Stewart 5
Deep Learning Analysis of Gene Expression Data for Breast Cancer Classification AS Y.P. Manawadu.
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.
Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
Figure 2 Multiscale modelling in oncology
Volume 60, Issue 6, Pages (December 2011)
Colorectal Cancer: Current “Standard” Uses for Molecular Testing
Focus on breast cancer Cancer Cell
Jean-Charles Nault, Peter R. Galle, Jens U. Marquardt 
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer  Meng Zhou, Long Hu, Zicheng.
Frank Detterbeck, MD  Journal of Thoracic Oncology 
Volume 143, Issue 3, Pages e2 (September 2012)
Predicted location and functional classification of differentially expressed transcripts. Predicted location and functional classification of differentially.
Published online September 20, 2017 by JAMA Surgery
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
Molecular Classification of Non–Muscle-Invasive Bladder Cancer (pTa Low-Grade, pT1 Low-Grade, and pT1 High-Grade Subgroups) Using Methylation of Tumor-Suppressor.
Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.
Ali Shamseddine,MD,FRCP
Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.
Target disease and target populations for 21st century vaccine developmentIncluded in the list are the agents of infectious diseases for which vaccines.
ADAM8 is overexpressed in human breast cancer AADAM8 mRNA expression in samples from breast tumor and normal breast tissue was analyzed using the Oncomine.
Correlation between Pten/p53 status and AKT pathway activity in BC and effect on clinical outcome Box plot for p53‐pathway activity in p53 wild‐type and.
Systems medicine-based approaches in interstitial lung diseases seek to analyse biological products (e.g. Systems medicine-based approaches in interstitial.
Three-year DFS rates of T x N subsets of the ACTS-CC trial and IDEA study.19 Annotation: definitions of DFS in ACTS-CC and IDEA were different. Three-year.
Landscape of the TME in gastric cancer and characteristics of TME subtypes. Landscape of the TME in gastric cancer and characteristics of TME subtypes.
TDP1 and TOP1 protein levels vary widely in colorectal cancer (CRC) patient samples. TDP1 and TOP1 protein levels vary widely in colorectal cancer (CRC)
Focus on breast cancer Cancer Cell
Molecular signatures are independent of tumor stage and grade.
MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.
Influence of ASGR2 expression on survival.
Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions  Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,
Epithelial and stromal percentage clusterin staining in normal nonadjacent colonic tissue and matched tumor tissue in 202 patients with stage II colorectal.
Presentation transcript:

Non ‐ invasive prognostic protein biomarker signatures associated with colorectal cancer by Silvia Surinova, Lenka Radová, Meena Choi, Josef Srovnal, Hermann Brenner, Olga Vitek, Marián Hajdúch, and Ruedi Aebersold EMBO Mol Med. Volume ():e August 7, 2015 ©2015 by European Molecular Biology Organization

The development of biomarker signatures for the prognosis of CRC Comprehensive clinicopathological features of CRC included regional disease localization within the colorectum, histological grading, and TNM staging classification. Silvia Surinova et al. EMBO Mol Med. doi: /emmm ©2015 by European Molecular Biology Organization

Biomarker signature of CRC outcome ABiomarker signature containing clinical factors and biomarker candidates predicting 5 ‐ year overall survival. Silvia Surinova et al. EMBO Mol Med. doi: /emmm ©2015 by European Molecular Biology Organization

Prediction of transcriptional CRC subtypes A, BProteins from the outcome biomarker signature were used to predict (A) three colon cancer subtypes (CCSs) in the GSE33113 dataset, and (B) five cellular phenotype subtypes in the GSE33113 and GSE14333 datasets. Silvia Surinova et al. EMBO Mol Med. doi: /emmm ©2015 by European Molecular Biology Organization

Biomarker signatures of additional prognostic CRC characteristics A, BSignatures for the prediction of (A) regional disease localization of colon (n = 131) and rectal (n = 71) tumors, and (B) localized (n = 150) and metastatic (n = 52) disease were also ob... Silvia Surinova et al. EMBO Mol Med. doi: /emmm ©2015 by European Molecular Biology Organization

Relationship between signature proteins and their functional annotation Proteins from the biomarker signatures, including the diagnostic signature from Surinova et al (2015), were associated and interlinked by the proteins they have in common. Silvia Surinova et al. EMBO Mol Med. doi: /emmm ©2015 by European Molecular Biology Organization